Abstract. The homeobox domain transcription factor PDX-1 is essential for pancreatic development and for the maintenance of ß-cell function. The participation of pancreatic duodenal homeobox factor-1 (PDX-1) in the transcription of several genes which are essential for glucose sensing and insulin synthesis underlines its key role in ß-cells of the pancreas. PDX-1 binds to the promoter of insulin, glucose transporter 2, and glucokinase and regulates their expression. By proteinprotein interaction, PDX-1 acts in concert with other transcription factors or coactivators at the level of the insulin promoter. Ectopic expression of PDX-1 together with other cofactors can re-program cells to behave like ß-cells and produce insulin. This property of PDX-1 opens new strategies for the treatment of diabetes. Little is known about its regulation at the posttranslational level. Here, we report on its DNA-binding activity, the nuclear import and on posttranslational modifications such as phosphorylation, glycosylation and sumoylation. Modulation of these posttranslational modifications may be an alternate strategy for treating diabetes.
Introduction
Diabetes mellitus is a heterogeneous metabolic disease, which is characterized by persistent hyperglycaemia resulting from defects in insulin production, insulin action or both. In 2006, according to the World Health Organization, at least 171 million people worldwide were suffering from diabetes, and it is estimated that by the year 2030, this number will double. As in many other countries of the world, Syria with its 16 million inhabitants has witnessed a tremendous change in nutritional habits and lifestyle during the last few decades. This has been reflected in an increase in metabolic diseases in general and diabetes in particular. The prevalence of diabetes in Syria is ~10%, which is comparable to the percentage found in neighbouring countries such as in Lebanon (13%), Egypt (6%), and Tunisia (9%) where an enormous increase is also expected within the next few years (1) . Diabetes can be associated with serious complications if not diagnosed early in life, and when not treated properly diabetes mellitus leads to blindness, dysfunction of the kidneys and the peripheral nervous system, microvascular damage and in general to a reduced life expectancy. Symptoms of diabetes are polyuria (frequent urination), polydipsia (increased thirst and consequent increased fluid intake) and polyphagia (increased appetite), although weight loss may occur. The complications of diabetes are far less common and less severe in people who have well controlled blood sugar levels (2,3). There are three major types of diabetes: type 1, type 2 and gestational diabetes (occurring during pregnancy) (4, 5) , which have similar symptoms and consequences, but different causes and population distributions. Type 1 diabetes, previously known as insulin-dependent diabetes (IDDM), childhood diabetes or also known as juvenile diabetes, is an auto-immune disease, due to destruction of the insulin-producing ß-cells in the pancreas. Type 1 diabetes accounts for 10-15% of people with the disease. It appears to be triggered by certain (mainly viral) infections, diet or chemicals in people genetically predisposed. Type 2 diabetes mellitus, previously known as adult-onset diabetes or non-insulin-dependent diabetes mellitus (NIDDM), is the most common form of diabetes accounting for 90% of all cases of diabetes mellitus. Moreover, between 10 and 20% of individuals older than 45 years of age in developed countries suffer from this form of diabetes, and the largest number is found in those aged 65 years and over, while in developing countries the largest number of people with this diabetes are in the age group 45 to 64 years. Worldwide rates are similar for men and women (6) . Type 2 diabetes is becoming increasingly common in children (7 (10, 11) . Type 2 diabetes is diagnosed upon a fasting plasma glucose concentration >7.0 mmol/l (126 mg/ dl) or with a glucose tolerance test, 2 h after the oral dose of a plasma glucose >11.1 mmol/l (200 mg/dl) (12) . Type 2 diabetes is manifested as the body develops a resistance to insulin and no longer uses the insulin properly. As the need for insulin rises, the pancreas gradually loses its ability to produce sufficient amounts of insulin to regulate blood sugar. Regulation of insulin gene expression in response to an increase in blood glucose levels is essential for maintaining normal glucose homeostasis.
The required insulin level is tightly and cooperatively regulated by transcription factors, nutrients and hormones. The islet of Langerhans is the functional section of the endocrine pancreas where the insulin-producing ß-cells represent the majority of the endocrine cell population. In addition α, δ and pancreatic polypeptide PP(F) cells are found in the islets which produce glucagon, somatostatin and PP, respectively. Pancreatic ß-cells act as glucose sensors and simultaneously integrate different signals to synthesize and secret insulin. Glucose enters the ß-cells through glucose transporter 2 (GLUT2) and is then phosphorylated by glucokinase to produce glucose-6-phosphate. Both GLUT2 and glucokinase expression is regulated by a transcription factor called PDX-1. In δ cells PDX-1 regulates the expression of somatostatin (13, 14) . In addition to ß-cells, δ cells also express PDX-1.
The role of PDX-1 in diabetes mellitus type 2
Among the several molecular events which are implicated in the manifestation of diabetes mellitus, mutations in genes whose gene products affect the ability of ß-cells to secrete insulin play an essential role. In rare forms of diabetes, mutations of only one gene can result in disease. However, in type 2 diabetes many genes are thought to be involved (15) . Among those genes which are expressed in ß-cells of the pancreas is the pancreatic duodenal homeobox factor-1 (PDX-1) which is also known as IDX-1, STF-1 and Igf-1. In this review we will use the abbreviation PDX-1. The human PDX-1 gene is located on chromosome 13q 12.1. It consists of two exons spanning a region of ~6 kb (16) . Although mutations in the PDX-1 gene are rare, all of the known mutations affect transcription of the insulin gene with an impaired response to elevated levels of glucose (17, 18) .
Mutations in the PDX-1 gene lead to a decrease in the binding activity of PDX-1 protein to the insulin promoter which is accompanied by reduced transcription of insulin in response to hyperglycaemia (19) .
The early-onset type 2 diabetes mellitus which is also called maturity-onset diabetes of the young (MODY 4), is clearly linked to an inactivating mutation in the PDX-1 gene (20, 21) . In addition to the regulation of the expression of insulin, PDX-1 also regulates early pancreatic development (22, 23) . Targeted disruption of the PDX-1 gene in mice results in abnormalities of the pancreas. Jonsson et al (24, 25) reported that mice homozygous for the PDX-1 deletion selectively lacked a pancreas at birth. In a ß-cell-specific knockout of the PDX-1 gene, mice developed an adult-onset, non-insulin-resistant type of diabetes (26) . These models further support the notion that mutations in the PDX-1 gene contribute to the development of type 2 diabetes in humans. Furthermore, pancreas abnormalities are connected with an inactivating mutation in exon 1 of PDX-1 (21) . In addition, a heterozygote with a frame-shift mutation within the PDX-1 gene coding region, which resulted in a truncated, nonfunctional protein, has been identified in children born with pancreatic agenesis (23, 27) .
During organogenesis PDX-1 is widely expressed in all cells differentiating into the exocrine and endocrine components of the pancreas whereas in the mature pancreas PDX-1 expression is predominantly restricted to the insulinproducing islet ß-cells. The replacement of islet cells is considered to be the optimal treatment for type 1 diabetes mellitus. However the availability of human islet cells for transplantation is rather limited. Ferber et al reported that ectopic expression of PDX-1 in liver cells could re-program the hepatic tissues to pancreatic ß-cell characteristics with a secretion of insulin (28) . It was recently shown that human bone marrow-derived mesenchymal stem cells could be induced to differentiate into functional insulin-producing cells by introduction of PDX-1 (29) . Thus, these results show that PDX-1 has the capacity to re-program extra pancreatic tissue towards a ß-cell phenotype and function. This observation was later confirmed by different groups using adenoviral vector constructs for gene transfer (30) (31) (32) .
Differentiation of embryonic stem (ES) cells into insulinsecreting cells is an additional technique being promoted for the future therapeutic treatment of diabetes mellitus. It was previously shown that a synergistic expression of PDX-1 and NeuroD1 which is known to be regulated downstream of neurogenin 3 is sufficient for the maintenance of the properties of insulin-producing cells derived from ES cells (33, 34) . Furthermore, adult tissue cells from the liver, intestinal epithelium-derived cells, and certain populations of bone marrow cells were shown to have the potential to differentiate into insulin-producing cells with the help of PDX-1 ( Fig. 1) (35-37) . Thus, these experiments provide the potential for the treatment of diabetes mellitus.
At the level of the insulin gene promoter, PDX-1 interacts with other proteins such as ß2/NeuroD1, E47/Pan1, the high mobility group protein I (38), the p300 coactivator (39) and Bridge-1 (40) . The region of the insulin gene promoter to which PDX-1 binds is essential for regulation of insulin gene expression (41) . Histone H4 acetylation plays an important role in regulated gene expression (42) . Glucose-mediated hyperacetylation of histone H4 depends on the recruitment of the histone acetyltransferase p300 by PDX-1 (43) . PDX-1 regulates insulin expression under low and high concentrations of glucose. Upon high glucose concentrations, PDX-1 mediates hyperacetylation of histone H4 and increases insulin gene expression. Upon low glucose concentrations, PDX-1 interacts with the histone deacetylases HDAC-1 and HDAC-2, which causes deacetylation of histone H4 and the downregulation of insulin gene expression. PDX-1 becomes phosphorylated at different residues depending on the concentration of glucose, which may determine its interaction with p300 or HDAC-1/2. This observation was further supported by experiments where cells were treated with okadaic acid which inhibits dephosphorylation of PDX-1. Okadaic acid treatment enables PDX-1 to bind efficiently to the histone acetyltransferase p300 (44) .
Low concentrations of insulin have an apoptosis-preventing activity. It was demonstrated that this antiapoptotic activity is mediated directly by PDX-1. Insulin stimulates the DNAbinding activity of PDX-1 in human islet cells (45) , and it stimulates a modest and transient increase in the PDX-1 protein expression (46) .
Although it is clear that PDX-1 functions as a transcription factor, there is some indication that PDX-1, probably with corepressor molecules, might also repress genes such as glucagon (26, 47) . 
Molecular aspects of the PDX-1 protein
The PDX-1 gene codes for a protein with 283 amino acids. The PDX-1 protein sequence is very homologous among different species. The N-terminus contains the transactivation domain. The middle region contains a homeodomain, which is responsible for DNA binding and protein-protein interactions as a transcriptional activation mechanism. The role of the C-terminus is poorly understood. There are indications that the C-terminus has an inhibitory function whereas other data show that the C-terminus is required for full transactivation (17, 48, 49) . The C-terminus harbours an evolutionarily conserved region, which mediates the interaction with the PDX C-terminus interacting factor-1 (PCIF-1). PCIF-1 inhibits PDX-1 transactivation in a specific and dose-dependent manner supporting the view that the Cterminus is necessary for transactivation. The polypeptide chain contains a nuclear localization signal (NLS) consisting of seven amino acids (RRMKWKK) that is conserved in mice, rats and humans. In the middle part of the protein is a proline-rich domain, which is implicated in the heterodimerization with the DNA-binding protein PBX-1 (50). Liu et al (51) suggested that PBX-1, a member of the TALE (3 amino acid loop extension) class of homeodomain transcription factors, is essential for normal development and function of the pancreas. Furthermore, PBX-1 and PDX-1 form a complex that regulates the somatostatin (SST) gene transcription cooperatively (52) . It is possible that through its interactions with PDX-1, PBX-1 may play an important role in the early developmental stage of the pancreas (53) .
Within the homeobox domain, PDX-1 contains an Antennapedia-like domain which allows it to permeate into cells (54) . The Antennapedia sequence includes the abovementioned nuclear localization signal (55, 56 ) and a sequence motif KIWFQN which seems to be important for its DNAbinding activity (Fig. 2) (49) .
At low glucose concentrations PDX-1 protein localizes exclusively in the cytoplasm. Incubation of islets with high glucose concentrations results in a rapid translocation of PDX-1 to the nucleus. Overexpression experiments with stress-activated protein kinase 2 (SAPK2) as well as inhibition studies with SB203580, a specific inhibitor of SAPK2, revealed that glucose regulates the insulin gene promoter through activation and nuclear translocation of PDX-1 via the SAPK2 pathway (57, 58) . Wortmannin, a PI3 kinase inhibitor, also inhibits the glucose-or insulinstimulated nuclear translocation of PDX-1 (59). The inactive cytoplasmic form of PDX-1 migrates at a molecular weight of 31 kDa whereas the nuclear-activated form migrates more slowly at 46 kDa. Phosphorylation may induce a conformational change in PDX-1 which affects its mobility on SDSpolyacrylamide gels. It was further shown that PDX-1 is modified by SUMO-1 (small ubiquitin-related modifier 1), which may be responsible for the increase in molecular mass by ~15 kDa. The sumoylated PDX-1 is located in the nucleus and is found to be more stable than the non-sumoylated form (60) .
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase, which is constitutively active in resting cells and is inactivated by insulin. It was recently shown that PDX-1 is phosphorylated in vivo on serine 61 and/or serine 66 in pancreatic ß-cells by GSK3, and this phosphorylation targets the protein for degradation by the proteasome (61) . It was also clear from this study that serine 61 and/or serine 66 phosphorylation do not modulate PDX-1 activity.
PDX-1 is also posttranslationally modified by O-linked N-acetylglucosamine (62) . Furthermore, an elevated glucose concentration leads to an increase in glycosylation which correlates with an increase in DNA-binding activity of PDX-1 and insulin secretion of ß-cells. Mass spectrometry analysis revealed that PDX-1 interacts with the two regulatory subunits of the kinase DNA-PK namely Ku70 and Ku80. PDX-1 is not only a binding partner for subunits of DNA-PK but is also phosphorylated by DNA-PK at least in vitro. After γ-radiation PDX-1 is phosphorylated at threonine 11 by DNA-PK and is then rapidly degraded. This degradation proceeds with a rapid reduction in the activation of the insulin promoter and a decrease in the expression of GLUT2 and glucokinase (63) . Per-Arnt-Sim kinase (PASK) is another enzyme which phosphorylates PDX-1 at least in vitro at threonine 152. By using point mutations at this position, it was found that phosphorylation at threonine 152 inhibits nuclear uptake of PDX-1 in response to elevated glucose concentrations (64).
Concluding remarks
The functions of the PDX-1 gene and protein have been extensively studied. There is promising progress in redirecting various cell types to behave like ß-cells and to produce insulin. However, the knowledge concerning posttranslational modifications of the PDX-1 protein and its interaction with other regulatory proteins is at the onset. The knowledge of the proteomic properties of PDX-1 is essential in order to develop new strategies for the treatment of diabetes mellitus.
